Floatz logo

Ilixadencel

Gastric Adenocarcinoma

MendusCell therapyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

65 Active assets in the Gastric Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Boehringer Ingelheim
Phase 3BB
TRASTUZUMAB
Boehringer Ingelheim
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
Eloxatin
Shanghai Zhongshan Hospital
Phase 3BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Ilixadencel is also rated in:

renal cell carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →